BD (company)

BD (company)
BD (company) · Public domain · source
Name	Becton, Dickinson and Company
Trade name	BD
Type	Public
Industry	Medical technology
Founded	1897
Founder	Maxwell Becton; Fairleigh S. Dickinson
Headquarters	Franklin Lakes, New Jersey, United States
Revenue	(2025) — see Financial Performance
Num employees	(2025) — see Global Operations and Manufacturing

BD (company)

Becton, Dickinson and Company is an American medical technology corporation that develops, manufactures, and sells medical devices, instrument systems, and reagents for healthcare institutions, life science researchers, clinical laboratories, and the pharmaceutical industry. Founded in the late 19th century by Maxwell Becton and Fairleigh S. Dickinson, the company expanded from needle and syringe production into a diversified portfolio encompassing diagnostics, bioscience tools, and safety-engineered devices. BD's operations intersect with hospitals, laboratories, pharmaceutical firms, and public health organizations across North America, Europe, and Asia.

History

Becton, Dickinson and Company's origins trace to 1897 when founders Maxwell Becton and Fairleigh S. Dickinson established a medical device enterprise that evolved amid the Progressive Era, interacting with contemporaries such as Eli Lilly and Company, Johnson & Johnson, Pfizer, Merck & Co., and Roche. In the 20th century BD expanded product lines during periods marked by the Spanish flu pandemic, the interwar years, and post-World War II industrial growth alongside firms like Becton Dickinson — note this is the subject — and competitors including Medtronic, Baxter International, GE Healthcare, and Siemens Healthineers. Strategic moves in the late 20th and early 21st centuries included acquisitions and international expansion engaging markets in United States, United Kingdom, Germany, Japan, and China, while navigating regulatory regimes exemplified by U.S. Food and Drug Administration and European Medicines Agency. The company responded to global health crises such as the HIV/AIDS pandemic and the COVID-19 pandemic through product adaptations, partnerships, and supply chain adjustments involving logistic partners including UPS, FedEx, Maersk, and DHL.

Products and Services

BD's portfolio includes safety-engineered syringes, needles, infusion therapy systems, diagnostic instruments, specimen collection systems, and reagents that serve hospitals, clinical laboratories, and research institutions such as Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, and UCLA Health. The company's life sciences offerings support workflows used by National Institutes of Health, Centers for Disease Control and Prevention, World Health Organization, pharmaceutical developers like Novartis, GlaxoSmithKline, and biotech firms such as Amgen and Genentech. Point-of-care diagnostic platforms compete with systems from Abbott Laboratories, Siemens Healthineers, and Thermo Fisher Scientific while BD's cytometry and cell-processing tools intersect with applications at institutions like Broad Institute and Fred Hutchinson Cancer Center. BD also provides training, technical services, and software solutions that interface with hospital information systems from vendors like Cerner and Epic Systems.

Research, Innovation, and Acquisitions

BD has pursued research collaborations with academic centers including Harvard Medical School, Stanford University School of Medicine, University of Oxford, University of Cambridge, and Karolinska Institutet, and has acquired technology firms and product lines from corporations such as CareFusion, CRISPR Therapeutics collaborators, and divisions of Thermo Fisher Scientific and Baxter International. The company invests in internal R&D and translational programs connecting to grant-funding bodies like National Science Foundation and Wellcome Trust while filing patents that cite prior art from entities including IBM Research and Bell Labs. Strategic acquisitions over the decades have included businesses that enhanced BD's diagnostic, biosciences, and medication management capabilities, aligning BD with markets served by Eurofins Scientific, SGS, and LabCorp. Collaborative innovation projects have linked BD products to clinical trials registered with ClinicalTrials.gov and regulatory submissions filed with the U.S. Food and Drug Administration.

Corporate Governance and Leadership

BD is governed by a board of directors and executive leadership that historically includes CEOs and officers with backgrounds at corporations such as Johnson & Johnson, Pfizer, Medtronic, GE Healthcare, and Procter & Gamble. Its governance framework adheres to listing standards of the New York Stock Exchange and reporting obligations to the Securities and Exchange Commission. Institutional shareholders frequently include asset managers like BlackRock, Vanguard Group, State Street Corporation, Fidelity Investments, and pension funds such as CalPERS. Executive compensation, succession planning, and corporate strategy have been topics of engagement with proxy advisory firms including Institutional Shareholder Services and Glass Lewis.

Financial Performance

BD's financial reporting follows U.S. Generally Accepted Accounting Principles and discloses revenue, operating income, net earnings, and cash flows in quarterly and annual filings with the Securities and Exchange Commission. Revenues are influenced by healthcare spending trends involving payers such as Centers for Medicare & Medicaid Services and private insurers like UnitedHealth Group and Anthem, Inc., procurement practices of hospital systems such as HCA Healthcare and Community Health Systems, and capital investments by academic medical centers. Market analysts at firms like Goldman Sachs, Morgan Stanley, JPMorgan Chase, UBS, and Credit Suisse provide earnings estimates and coverage influencing the company's share price on the New York Stock Exchange. Debt ratings by agencies including Moody's Investors Service, Standard & Poor's, and Fitch Ratings inform capital markets operations.

Global Operations and Manufacturing

BD operates manufacturing, R&D, and distribution facilities across continents including sites in United States, Ireland, Switzerland, Singapore, India, China, and Brazil, supplying products through regional channels that interact with national health services such as the National Health Service (England), provincial health authorities in Canada, and ministries of health across Africa and Latin America. The company's supply chain encompasses contract manufacturers, logistics providers, and raw-material suppliers like manufacturers of plastics, stainless steel, and electronic components, and coordinates quality systems aligned with standards from International Organization for Standardization and certifications required by the U.S. Food and Drug Administration. Manufacturing strategies have involved automation, continuous improvement methodologies inspired by Toyota Production System, and digital transformation initiatives collaborating with technology partners like Siemens, Rockwell Automation, and Microsoft.

Corporate Responsibility and Legal Issues

BD engages in corporate responsibility programs addressing access to care, public health partnerships with World Health Organization, UNICEF, and non-profits such as Bill & Melinda Gates Foundation and Clinton Health Access Initiative, and sustainability reporting aligned with frameworks from Global Reporting Initiative and Sustainability Accounting Standards Board. The company has faced legal and regulatory challenges including product liability litigation, compliance matters with agencies like the U.S. Department of Justice, settlement actions akin to cases involving other medical device firms such as Stryker Corporation and Boston Scientific, and antitrust scrutiny comparable to matters handled by the Federal Trade Commission. BD has implemented compliance programs, quality remediation plans, and stakeholder engagement to address litigation outcomes and regulatory findings.

Category:Medical technology companies Category:Companies based in New Jersey Category:Companies listed on the New York Stock Exchange